HemoShear Therapeutics
HemoShear Therapeutics is a private, pre-commercial biotechnology company founded in 2008 in Charlottesville, Virginia, developing therapeutics for rare metabolic disorders, with a specific focus on Methylmalonic Acidemia (MMA), serving patients with serious inherited metabolic diseases.
- Company typePrivate
- Founded2008
- HeadquartersCharlottesville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What HemoShear Therapeutics does
HemoShear Therapeutics, Inc. is a private clinical-stage biotechnology company founded in 2008 and headquartered in Charlottesville, Virginia. The company develops therapeutic treatments for patients with rare metabolic disorders, with a specific focus on Methylmalonic Acidemia (MMA), a serious inherited metabolic disease with limited treatment options. The company operates in the drug development stage and has not yet commercialized any therapeutic product; its website currently displays a "Launching Soon" placeholder with email capture functionality, indicating preparation for a significant corporate or product milestone.
The company has sustained operations for over 15 years through multiple funding rounds totaling approximately $63.6 million, including a $40 million round in February 2021 led by Suvretta Capital Management with participation from Adage Capital Management and Janus Henderson Investors, and a subsequent $3.5 million exempt securities offering filed in November 2023. Early-stage funding included Small Business Innovation Research (SBIR) grants, seed capital, and venture financing. The leadership team includes a co-founder serving as Chief Scientific Officer, an interim CEO, a Chairman of the Board, and multiple finance executives, suggesting active corporate governance during the pre-commercial phase.
HemoShear Therapeutics' business model is consistent with a venture-backed preclinical or early-clinical biotech: revenue is not generated from product sales, and the company is funded through equity raises and grants to advance its drug development pipeline. With 11-50 employees and no disclosed commercial partnerships, the company appears to be in a development-focused stage preparing for either a clinical milestone disclosure, partnership announcement, or strategic transaction.
HemoShear Therapeutics firmographics
Firmographics- Name
- HemoShear Therapeutics
- Legal name
- HEMOSHEAR THERAPEUTICS, INC.
- Website
- https://hemoshear.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HemoShear Therapeutics is a private, pre-commercial biotechnology company founded in 2008 in Charlottesville, Virginia, developing therapeutics for rare metabolic disorders, with a specific focus on Methylmalonic Acidemia (MMA), serving patients with serious inherited metabolic diseases.
- Ownership category
- akta.pro rank
HemoShear Therapeutics industry classification
Industry- Product category
- Rare Metabolic Disease Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where HemoShear Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Charlottesville
- HQ country
- United States
- HQ region
- North America
Markets served
HemoShear Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
HemoShear Therapeutics product offering
Product offeringCore offering
HemoShear Therapeutics is a clinical-stage biotechnology company developing small-molecule therapeutics for rare metabolic genetic disorders, with its lead program focused on Methylmalonic Acidemia (MMA). The company uses a proprietary human disease modeling platform to identify and validate drug candidates that address the underlying pathology of these underserved diseases. No products are currently commercialized; the company is in pre-launch stage.
Product overview
HemoShear Therapeutics operates a minimal website displaying a "Launching Soon" placeholder. No specific products, modules, or service offerings are named or described in the available source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Methylmalonic Acidemia (MMA) Therapeutic Program Lead small-molecule therapeutic development program targeting Methylmalonic Acidemia (MMA), a rare inherited metabolic disorder, intended for patients with this genetic metabolic disease.
Companies that use HemoShear Therapeutics
Customer profileIdeal customer profiles1 record
HemoShear Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HemoShear Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights3 records
HemoShear Therapeutics competitors and assessment
Company assessmentDirect peers
- Ultragenyx Pharmaceutical: Commercial-stage rare genetic disease biotech with multiple approved therapies and active programs in inborn errors of metabolism. Highly comparable as both companies target rare inherited metabolic disorders with disease-modifying approaches.
- Aeglea BioTherapeutics: Clinical-stage biotech developing engineered human enzymes for rare metabolic disorders. Directly comparable therapeutic focus on metabolic diseases and similar development stage relative to HemoShear's pre-commercial posture.
- BridgeBio Pharma: Genetic disease-focused biotech with multiple subsidiary programs targeting rare Mendelian and metabolic conditions. Comparable business model of building multiple rare disease assets and similar focus on genetic disease therapeutics.
- Travere Therapeutics: Rare disease biotech with approved therapies and a pipeline focused on serious rare conditions including metabolic and genetic disorders. Comparable in size and therapeutic focus area.
- Taysha Gene Therapies: Clinical-stage gene therapy company focused on rare monogenic diseases of the central nervous system. Comparable as a rare disease biotech of similar maturity, though with gene therapy modality rather than HemoShear's small-molecule metabolic approach.
Broad incumbents
- BioMarin Pharmaceutical: Established rare disease specialist with multiple approved enzyme replacement and gene therapy products. Comparable as a benchmark for commercial rare metabolic disease execution, though significantly larger and broader in scope.
- Alexion (AstraZeneca Rare Disease): Global leader in rare disease therapeutics with deep expertise in metabolic and hematologic rare disorders. Comparable as a large incumbent operating in overlapping rare disease categories including metabolic conditions.
- Moderna: mRNA therapeutics platform with active rare disease programs including MMA. Comparable as a competitive threat in the MMA space through gene therapy/mRNA modality, though far larger and more diversified.
Emerging players
- Homology Medicines: Clinical-stage genetic medicines company developing gene therapy and editing approaches for rare genetic diseases. Comparable as a similarly-sized rare genetic disease biotech, though with a gene therapy modality vs. HemoShear's small-molecule/metabolic approach.
- Selecta Biosciences: Clinical-stage biotech developing immunomodulatory therapies for rare and serious diseases. Comparable as a similarly-sized clinical-stage rare disease biotech with comparable funding scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights4 records
Customer concentration
HemoShear Therapeutics social profiles
Digital presenceHemoShear Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
HemoShear Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
HemoShear Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HemoShear Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HemoShear Therapeutics
What does HemoShear Therapeutics do?
HemoShear Therapeutics is a clinical-stage biotechnology company developing small-molecule therapeutics for rare metabolic genetic disorders, with its lead program focused on Methylmalonic Acidemia (MMA). The company uses a proprietary human disease modeling platform to identify and validate drug candidates that address the underlying pathology of these underserved diseases. No products are currently commercialized; the company is in pre-launch stage.
Is HemoShear Therapeutics a public or private company?
HemoShear Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was HemoShear Therapeutics founded?
HemoShear Therapeutics was founded in 2008. It employs 11 to 50 people.
Where is HemoShear Therapeutics based?
HemoShear Therapeutics is headquartered in Charlottesville, United States, in the North America region.
Who are HemoShear Therapeutics's main competitors?
Direct peers on record are Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, BridgeBio Pharma, Travere Therapeutics and Taysha Gene Therapies. Broad incumbents are BioMarin Pharmaceutical, Alexion (AstraZeneca Rare Disease) and Moderna. Emerging players are Homology Medicines and Selecta Biosciences.
Does HemoShear Therapeutics have an API?
No public API is recorded for HemoShear Therapeutics.
What industry is HemoShear Therapeutics in?
HemoShear Therapeutics's product category is Rare Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 325412 and its SIC code is 2834.